Knowledge Base
Recent Additions
- OptiLeukin 2 – Guidelines for Use
- OptiLeukin 2 – Data Sheet
- Sustained T Cell Proliferation and Early Memory Retention with OptiLeukin™ 2 Recombinant IL-2
- InVitria Launches OptiLeukin 2 Recombinant Interleukin-2
- Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel
- InVitria Product Catalog – 2025
- LIF Leukemia Inhibitory Factor – Data Sheet
- Lacromin – Data Sheet
- Lysobac – Data Sheet
- Exbumin – Data Sheet
- OptiVERO – Data Sheet
- ITSE+A Animal-Free – Data Sheet
- ITSE Animal-Free – Data Sheet
- ITS Animal-Free – Data Sheet
- Cellastim S – Data Sheet
- Optiferrin – Data Sheet
- Optibumin 20 – Data Sheet
- Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?
- Optibumin 25 – Data Sheet
- InVitria Launches Optibumin 25 rHSA
- Cryopreservation Just Got Better with Optibumin® 25
- Retain and Protect Final Cell Product with Optibumin®, a Recombinant Human Serum Albumin (rHSA)
- OptiVERO – Guidelines for Use
- How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development
- Enhanced Cryopreservation of T Cells Using Optibumin®, Recombinant Human Serum Albumin (rHSA)
- Advancing Vaccine Excellence
- Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency
- Evolving Challenges in Closed-System Biomanufacturing
- T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO
- Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications
- Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy
- ITSE+A – Guidelines for Use
- Maintaining Viable Cell Count in Primary T Cells During Cell Washing Using Optibumin®
- Addressing Vaccine Stability And Cold Chain Challenges With Recombinant Human Serum Albumin To Enable Global Administration
- Cryoprotectant Additives, Including rHSA, Improve iNK and iT Cell Health & Viability During Cryopreservation
- Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations
- Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin
- VERO Expansion in the iCellis® Bioreactor with Chemically Defined and Blood Free Virus Production Media
- High-Quality Recombinant Human Serum Albumin (rHSA), Exbumin™, for Improved Cell Wash Buffer Preparation
- Chemically Defined Upstream and Downstream Lentivirus Production for High T Cell Transduction
- Optimizing the Performance of LNP and Liposome Therapeutics with Blood-Free Recombinant Albumin
- DMSO-Free Cryopreservation Formulation As An Alternative Cryopreservation Method For Cell-based Therapies
- DMSO-Free Cryopreservation of Mesenchymal Stem Cells in Chemically Defined Systems
- DMSO-Free Cryopreservation of Human T Lymphocytes in Chemically Defined Systems
- Formulation and Production of a Blood-free and Chemically Defined Virus Production Media for VERO Cells
- Evaluation of Transfection Reagents for High Titer Viral Vector Production in the iCELLis Nano Bioreactor
- Process Optimization for Lentivirus Production in the iCELLis® Nano Using a Chemically Defined, Animal Component Free HEK293 Media
- Exbumin – Reconstitution Application Note
- Lentivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield
- Emergence of Blood-Free Recombinant Human Albumin
- Accelerating Vaccine Development Through Use of Blood-Free Components
- OptiVERO – Virus Production Using VERO Cells in Flasks without Serum in Chemically Defined Cell Culture Media Application Note
- rHSA Reconstitution Video Protocol
- Optibumin – Safety Data Sheet
- Lysosure – Safety Data Sheet
- Lysobac – Safety Data Sheet
- Lysobac – Brochure – E.Coli Lysis
- Lysobac – Guidelines for Use
- ITSE AF – Safety Data Sheet
- ITSE AF – Guidelines for Use
- ITSE AF – Brochure
- ITS – Guidelines for Use
- ITS – Specifications
- Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note
- Exbumin – Safety Data Sheet
- Exbumin – Guidelines for Use
- Optiferrin – Product Brochure
- Optiferrin – Guidelines for Use
- Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes
- Cellastim S – Safety Data Sheet
- Cellastim S – Reconstitution Application Note
- Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin
- Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease
- Solving the Vaccine Supply Challenge
- Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times
- SARS-CoV2 and Influenza – Double Threat
- High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media
- Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease
- Transient Transfection Protocol – Enhancement of Transfection Efficiency Using Recombinant Transferrin with Serum-Free HEK293 Media
- Expansion of Adherent HEK293T Cells in Flasks in Chemically Defined Cell Culture Media
- Controlling Impurities in Cell Culture Media
- Recombinant Human Leukemia Inhibitory Factor for the Enhanced Expansion of Neural Stem Cells
- BioInnovation on Parade: Philly Stands Proud for BIO 2019!
- Using Recombinant Transferrin in the Expansion of Hematopoietic Stem Cells Application Note
- Explore the Latest Developments in T-reg Research and Clinical Application
- Exploring the Latest Research and Opportunities in T-reg Therapy
- Cellastim S – Recombinant Human Serum Albumin in the Generation of Functional Cardiomyocytes from Pluripotent Stem Cells
- ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy
- Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines
- OptiVERO – Virus Production Using VERO Cells with Microcarriers Without Serum in Chemically Defined Cell Culture Media
- Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture
- OptiVERO – Expansion of VERO Cells Without Serum in Chemically Defined Cell Culture Media
- Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial
- ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy
- Phacilitate 2019 and World Stem Cell Summit
- Join InVitria at ECI 2019
- Join InVitria at Phacilitate 2019
- Cellastim S – Guidelines for Use
- Happy Holidays from the InVitria Team!
- BIO Europe 2018: From Lab Innovations to Commercial Realities
- InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area
- BIO 2018: The Emergence of Gene & Cell Therapy
- InVitria at the American Association of Immunologists 2018 Conference
- Optiferrin – Recombinant Transferrin an Iron Transport Protein in Cell Culture Media
- InVitria’s Top Insights from ISCT 2018 – Montreal
- 3 Takeaways from the World Vaccine Congress 2018